Susvimo (ranibizumab)

Where it stands

Susvimo (ranibizumab) is authorised in the EU. The marketing authorisation holder is Roche Registration GmbH. The CHMP adopted a positive opinion on 2026-07-23, and the European Commission decision approving the product followed on 2026-09-18, about 57 days later.

The authorised indication is for adult patients with neovascular (wet) age-related macular degeneration (nAMD) who have achieved stable disease after previously responding to intravitreal treatment with a vascular endothelial growth factor (VEGF) inhibitor medicinal product. This is a defined subgroup, not the whole nAMD population. Eligibility depends on both a prior response and current disease stability.

The records do not include the product information, clinical trial data, dosing or the administration route. This analysis therefore covers only the regulatory status and the indication wording.

Regulatory pathway and designations

The records show two milestones: a CHMP positive opinion (2026-07-23) and the EC decision (2026-09-18). In general EU procedure, the CHMP opinion is the scientific recommendation. The EC decision converts it into a legally binding marketing authorisation valid across the EU. The Commission typically issues its decision within about 67 days of the opinion, and this timeline fits that pattern.

The only designation recorded is additional monitoring. The records do not show orphan status, conditional approval, exceptional circumstances or accelerated assessment. They also do not state the procedure type or the legal basis of the application, so none of these should be assumed.

Ranibizumab is already on the EU market. The records list Lucentis, Byooviz, Epruvy (previously Ranibizumab Midas), Ximluci and Vislyfa as authorised, and Fovlussea as having reached the opinion stage. The records do not say how Susvimo's application relates to these products, or whether any of them share its indication wording.

Safety and pharmacovigilance

Susvimo carries additional monitoring status. In EU practice, this means the product is under intensified pharmacovigilance scrutiny. Its package leaflet and product information carry a black inverted triangle, and healthcare professionals and patients are encouraged to report suspected adverse reactions. The status does not in itself mean a safety problem has been identified.

The records contain no safety data, such as adverse reaction profiles, risk management plan content, warnings, contraindications or post-authorisation commitments. Any statement about Susvimo's risks or risk-minimisation measures would go beyond the records and is not made here.

What to watch

First, the published product information and the EPAR. They will set out the full indication wording, the evidence base, the risk management plan and any conditions or additional risk-minimisation measures. The records do not contain these.

Second, the competitive landscape within ranibizumab. Fovlussea has reached the opinion stage, while five other ranibizumab products are already authorised. The records do not allow any comparison of positioning, and they contain no launch, pricing or reimbursement information.

Third, the additional monitoring status. It is normally reviewed over time, and the black triangle is removed once the status is lifted. The records give no timing for this, so any pharmacovigilance outputs after authorisation should be tracked as they are published.